Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical formulation company, reported deeply troubling Q3 FY26 results that underscore the severe operational and financial distress gripping the organisation. The company posted a net loss of ₹2.32 crores for the quarter ended December 2025, representing a 75.76% deterioration from the ₹1.32 crores loss recorded in Q3 FY25. With a market capitalisation of just ₹45.00 crores, the stock plunged 5.91% following the results announcement, closing at ₹6.85 on February 13, 2026—a mere 4.26% above its 52-week low of ₹6.57.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Vista Pharmaceuticals Ltd has reached a new 52-week low price of Rs.6.57, marking a significant decline amid ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Vista Pharmaceuticals Ltd’s stock touched a new 52-week low of Rs.7 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued performance metrics.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024, but the analysis below reflects the stock’s current position as of 26 January 2026, incorporating the latest fundamentals, returns, and financial metrics available today.

Vista Pharmaceuticals Ltd touched a new 52-week low of Rs.7.61 today, marking a significant decline in its share price amid a broader market downturn and persistent company-specific headwinds.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial data presented here are based on the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects.

Vista Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational performance. The recent assessment highlights concerns across multiple parameters including quality, valuation, financial trends, and technical outlook, underscoring the stock's current position within a difficult market environment.

Vista Pharmaceuticals Ltd witnessed an exceptional surge in buying interest on 19 Nov 2025, hitting the upper circuit with only buy orders in the queue. The stock recorded a remarkable 20.00% gain in a single trading session, significantly outperforming the Sensex’s modest 0.33% rise, signalling a potential multi-day circuit scenario driven by extraordinary demand and absence of sellers.

Vista Pharmaceuticals has reached a new 52-week low of Rs.7.63 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and valuation metrics.